Clinical trials: MSA - Multiple System Atrophy
Multiple System Atrophy
An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy
The primary objective of the trial is to describe the long-term safety and tolerability of TEV-56286 administered orally for the treatment of adult participants with Multiple System Atrophy (MSA).
- Trial name
- NCT07197866
- Testing
- TEV-56286
- Where
- 41 sites in United States, France and 5 more
- Volunteers
- 200 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
Parkinson Disease
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of anle138b in Parkinson's Disease
The purpose of this study is to determine the safety, tolerability and blood levels of orally administered anle138b as well as the effect of food and early signs of efficacy in patients with mild to moderate Parkinson´s disease.
- Trial name
- NCT04685265
- Testing
- anle138b
- Where
- United Kingdom
- Volunteers
- 70 people
- Sponsor
- MODAG GmbH
Multiple System Atrophy
"An Intermediate Size Patient Population Expanded Access Protocol to Evaluate the Safety and Efficacy of Allogeneic HB-adMSCs (Hope Biosciences - Adipose Derived Mesenchymal Stem Cells) for the Treatment of Multiple System Atrophy."
This expanded access protocol is part of IND 32226 to evaluate efficacy and safety of multiple intravenous administrations of allogeneic HB-adMSCs for the treatment of Multiple System Atrophy for up to 7 adult patients who pass…
- Trial name
- NCT07238062
- Testing
- HB-adMSCs - Hope Biosciences Adipose Derived Mesenchymal Stem Cells
- Where
- United States
- Sponsor
- Hope Biosciences Research Foundation
the Treatment of Multiple System Atrophy Parkinsonian Variant (MSA-P)
The Safety, Tolerability, and Efficacy of Dopaminergic Neural Progenitor Cells (XS411CN Cell Injection) for the Treatment of Multiple System Atrophy Parkinsonian Variant (MSA-P).
A Phase I Study to Assess the Safety, Tolerability and Efficacy of dopaminergic neural progenitor cells (XS411CN cell injection) for the treatment of multiple system atrophy Parkinsonian variant (MSA-P).
- Trial name
- NCT07617012
- Testing
- XS411CN Cell Injection
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.
Neurologic Disorders, Nervous System Diseases
Neurologic Stem Cell Treatment Study
This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1/3 of the nasal passages in order to determine if such a treatment will…
- Conditions
- Neurologic Disorders, Nervous System Diseases, Neurodegenerative Diseases, Neurological Disorders
- Trial name
- NEST (NCT02795052)
- Testing
- Intravenous and Intranasal BMSC
- Where
- 3 sites in United States, United Arab Emirates
- Volunteers
- 500 people
- Sponsor
- MD Stem Cells
Multiple System Atrophy
Observational Study in Multiple System Atrophy
Talisman is global clinical study (20058N) in Multiple System Atrophy (MSA) patients. It will be conducted in two regions (China and the European Union [EU]).
- Trial name
- TALISMAN (NCT05453058)
- Testing
- plasma NfL and brain MRI (vMRI, DTI, and ASL [if feasible]) only for the EU cohort
- Where
- 8 sites in China
- Volunteers
- 90 people
- Sponsor
- H. Lundbeck A/S
Parkinson's Disease, Multiple System Atrophy, Parkinson Variant
Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy
The objective of this study is to describe disease progression in study participants diagnosed with early Parkinson's Disease or Multiple System Atrophy - Parkinsonian Type up to 18 months as delineated by clinical and…
- Conditions
- Parkinson's Disease, Multiple System Atrophy, Parkinson Variant, Multiple System Atrophy
- Trial name
- NCT05699460
- Testing
- This is an observational study.
- Where
- 11 sites in United States, Poland
- Volunteers
- 73 people
- Sponsor
- AskBio Inc
Parkinson Disease, Multiple System Atrophy
Safety, Tolerability, and Pharmacokinetics of Exidavnemab in Patients With Parkinson's Disease and Patients With Multiple System Atrophy
The primary objective of this study is to assess the safety and tolerability of exidavnemab after multiple dosing versus placebo.
- Trial name
- EXIST (NCT06671938)
- Testing
- exidavnemab
- Where
- 7 sites in Poland, Spain
- Volunteers
- 38 people
- Sponsor
- BioArctic AB
Multiple System Atrophy
A Biomarker Study of ATH434 in Participants With MSA
This study will assess the safety and efficacy of ATH434 in participants with a clinical diagnosis of Multiple System Atrophy
- Trial name
- NCT05864365
- Testing
- ATH434
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Alterity Therapeutics
Symptomatic Neurogenic Orthostatic Hypotension (NOH), Non-diabetic Neuropathy
A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa
The purpose of this study is to see whether droxidopa is effective in treating symptoms of neurogenic orthostatic hypotension in patients with Primary Autonomic Failure (Pure Autonomic Failure, Multiple System Atrophy…
- Conditions
- Symptomatic Neurogenic Orthostatic Hypotension (NOH), Non-diabetic Neuropathy, Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency
- Trial name
- NOH301 (NCT00782340)
- Testing
- Droxidopa
- Where
- 21 sites in United States, Canada
- Volunteers
- 263 people
- Sponsor
- Chelsea Therapeutics
Multiple System Atrophy
Trial to Evaluate the Efficacy and Safety of KM-819 Treatment to Slow the Progression of Multiple System Atrophy (MSA)
This trial will the efficacy of KM-819 compared to placebo in subjects with MSA for slowing the progression of MSA.
- Trial name
- NCT05695378
- Testing
- KM-819
- Where
- South Korea
- Volunteers
- 68 people
- Sponsor
- Kainos Medicine Inc.
Multiple System Atrophy
Post-Trial Access to ATH434 for Patients With Multiple System Atrophy
This multicenter post-trial access program is designed to provide ATH434 orally BID to eligible patients who completed Phase 2 studies ATH434-201 or ATH434-202, and who may benefit from this treatment according to the evaluation…
- Trial name
- NCT07531433
- Testing
- ATH434
- Sponsor
- Alterity Therapeutics
Symptomatic Neurogenic Orthostatic Hypotension
Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
A Phase 3 study to evaluate efficacy, safety, and tolerability of ampreloxetine (TD-9855) in subjects with primary autonomic failures (MSA, PD, or PAF) and symptomatic nOH with up to 4 weeks of treatment.
- Trial name
- SEQUOIA (NCT03750552)
- Testing
- ampreloxetine
- Where
- 125 sites in United States, Australia and 17 more
- Volunteers
- 195 people
- Sponsor
- Theravance Biopharma
MSA - Multiple System Atrophy, MSA
Autologous Stem Cell Therapy in Patients With Multiple System Atrophy
This study investigates the safety and efficacy of autologous stem cell therapy in patients with Multiple System Atrophy (MSA), a rare and progressive neurodegenerative disorder characterized by autonomic failure, parkinsonism…
- Trial name
- NCT07465198
- Testing
- MSCs
- Where
- Poland
- Volunteers
- 50 people
- Sponsor
- Biocells Medical
Parkinson's Disease (PD), Multiple System Atrophy (MSA)
[18F]ACI-15916 PET in α-synucleinopathies
The goal of this clinical trial is to test whether we can reliably and safely measure the accumulation of pathological protein α-synuclein [involved in some diseases such as Parkinson's disease, Lewy body dementia and Multiple…
- Conditions
- Parkinson's Disease (PD), Multiple System Atrophy (MSA), Dementia With Lewy Bodies (DLB)
- Trial name
- NCT06891703
- Testing
- [18F]ACI-15916
- Where
- Sweden
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- AC Immune SA
Symptomatic Neurogenic Orthostatic Hypotension (NOH), Parkinson's Disease
Fipamezole in Neurogenic Orthostatic Hypotension
The purpose of this study is to determine whether Fipamezole is effective in the treatment of orthostatic hypotension and related symptoms in multiple system atrophy and Parkinson's disease.
- Conditions
- Symptomatic Neurogenic Orthostatic Hypotension (NOH), Parkinson's Disease, Multiple System Atrophy
- Trial name
- Foehn (NCT00758849)
- Testing
- Fipamezole
- Where
- 4 sites in France, Portugal
- Volunteers
- 24 people
- Sponsor
- Juvantia Pharma Ltd
Symptomatic Neurogenic Orthostatic Hypotension, MSA
Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of ampreloxetine in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure
- Conditions
- Symptomatic Neurogenic Orthostatic Hypotension, MSA, Parkinson's Disease (PD), Pure Autonomic Failure (PAF)
- Trial name
- REDWOOD (NCT03829657)
- Testing
- ampreloxetine
- Where
- 82 sites in United States, Australia and 17 more
- Volunteers
- 203 people
- Sponsor
- Theravance Biopharma